Conditions: Asthma
Keywords: Asthma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 584
Healthy volunteers: no

Brief summary:
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Detailed description:

Arms:
arm 1: Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50. arm 2: Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50. arm 3: Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50. arm 4: Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

Interventions: intervention 1: Placebo intervention 2: MEDI9929 70 mg intervention 3: MEDI9929 210 mg intervention 4: MEDI9929 280 mg
Intervention descriptions: intervention 1: Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50. intervention 2: Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50. intervention 3: Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50. intervention 4: Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

Protocol document: